felin
infecti
periton
fip
fatal
immunemedi
diseas
trigger
infect
felin
coronaviru
fcov
felin
infecti
periton
viru
fipv
virul
biotyp
felin
enter
coronaviru
fecv
low
pathogen
fcov
induc
mild
enter
kitten
analysi
fipv
fecv
genom
suggest
fipv
may
aris
fecv
seri
genom
mutat
provid
viru
abil
replic
within
cell
monocyt
lineag
thu
dissemin
throughout
bodi
vennema
et
al
pedersen
et
al
chang
et
al
pathogenesi
fip
complet
understood
develop
viral
quasispeci
felin
immun
respons
infect
consid
key
pathogen
event
usual
predominantli
humor
immun
respons
consid
ineffect
viru
neutral
sinc
presenc
antibodi
could
enhanc
uptak
fcov
macrophag
pedersen
interferon
gamma
ifng
play
import
role
cell
mediat
respons
mutat
felin
coronaviru
strain
fcov
involv
pathogenesi
felin
infecti
periton
fip
aim
studi
establish
combin
silico
vitro
approach
assess
felin
leukocyt
product
ifng
respons
select
peptid
nucleocapsid
protein
n
fcov
aim
design
bioinformat
approach
potenti
immunogen
peptid
protein
n
correspond
sequenc
residu
detect
fcov
fip
cat
virul
strain
fcov
healthi
cat
avirul
strain
fip
healthi
cat
mix
strain
peptid
sham
solut
incub
whole
blood
cat
healthi
chronic
diseas
fip
ifng
concentr
measur
plasma
use
elisa
system
rtpcr
express
ifng
mrna
also
evalu
incub
peptid
sham
solut
whole
blood
clinic
healthi
cat
mean
plasma
concentr
ifng
sampl
incub
peptid
decreas
express
ifngmrna
chang
compar
sham
solut
except
cat
chronic
diseas
probabl
preactiv
immun
respons
cat
respond
avirul
mix
peptid
increas
concentr
ifng
express
ifng
mrna
combin
approach
employ
studi
allow
us
identifi
potenti
immunogen
peptid
fcov
n
protein
modul
product
ifng
especi
cat
preactiv
cell
mediat
respons
elsevi
bv
right
reserv
type
immun
respons
deposit
macrophag
virusantibodi
complex
around
small
venul
lead
pyogranulomat
vascul
respons
format
effus
typic
wet
fip
strong
cellmedi
immun
respons
develop
earli
stage
infect
viru
replic
could
lower
infect
limit
success
clear
evid
clinic
sign
convers
cellmedi
respons
weak
unabl
reduc
viru
replic
intermedi
respons
also
occur
continu
releas
virokin
chemokin
recruit
neutrophil
macrophag
infect
site
lead
format
pyogranuloma
typic
dri
fip
dri
fip
may
also
becom
effus
termin
stage
diseas
immun
system
collaps
thu
develop
fip
depend
balanc
humor
cellular
immun
respons
pedersen
cytokin
interferong
ifng
one
main
modul
cell
mediat
immun
berg
et
al
ifng
shift
immun
respons
thelper
thelper
consequ
enhanc
immun
cytotox
activ
due
activ
macrophag
cell
type
immun
protect
host
develop
diseas
even
infect
pedersen
coronavirus
contain
least
three
main
structur
protein
spike
membran
nucleocapsid
n
nucleocapsid
n
protein
one
produc
viral
protein
viral
infect
may
exert
sever
function
primarili
involv
encapsid
packag
viral
genom
rna
addit
structur
role
also
particip
viral
rna
transcript
replic
translat
lai
canavagh
modul
metabol
host
cell
eleouet
et
al
surijt
et
al
sever
studi
identifi
antigen
determin
n
protein
human
anim
coronavirus
demonstr
n
protein
one
immunodomin
antigen
cov
famili
collisson
et
al
liu
et
al
zhao
et
al
n
protein
may
play
import
role
pathogenesi
fip
differ
recombin
vaccin
base
n
protein
alreadi
test
case
prove
effect
prevent
progress
fip
suggest
cell
mediat
immun
fipv
antigen
induc
vaccin
wasmoen
et
al
hohdatsu
et
al
therefor
n
protein
could
suitabl
vaccin
candid
precis
identif
tcellstimul
epitop
repres
difficult
task
import
prerequisit
accur
epitop
map
formul
vaccin
immunotherapi
systemat
approach
base
upon
synthesi
test
larg
set
overlap
peptid
expens
contrast
bioinformat
predict
extrem
cheap
use
select
potenti
immunogen
peptid
region
reduc
number
peptid
screen
strategi
combin
predict
power
theoret
approach
experiment
vitro
vivo
approach
allow
reliabl
rapid
identif
cell
stimul
epitop
schirl
et
al
mani
webbas
databas
predict
algorithm
avail
appli
success
predict
tcell
stimul
epitop
infecti
diseas
cancer
autoimmun
allergi
studi
possibl
cell
mediat
immun
respons
induc
n
protein
investig
use
comput
predict
method
vitro
assay
assess
thelper
respons
specif
potenti
immunogen
peptid
n
protein
design
bioinformat
approach
product
ifng
assess
incub
felin
leucocyt
peptid
method
employ
assess
ifng
product
base
incub
whole
blood
differ
protein
n
peptid
cell
viabil
provid
method
alreadi
evalu
previou
studi
appear
greater
incub
gelain
et
al
blood
sampl
ml
collect
jugular
vein
privat
own
cat
inform
consent
obtain
owner
put
edtaco
tube
specif
blood
cat
cat
use
assess
ifng
product
elisa
system
see
detail
time
sampl
cat
diagnos
clinic
healthi
n
show
symptom
diseas
fip
n
hepat
lipidosi
n
neoplasia
n
chronic
gastroenter
n
cardiopathi
n
bone
fractur
n
trauma
n
blood
addit
cat
cat
ad
use
assess
express
mrna
code
felin
ifng
see
detail
sampl
cat
diagnos
clinic
healthi
sampl
complet
blood
cell
count
cbc
obtain
use
autom
haematolog
analys
sysmex
togeth
manual
differenti
leukocyt
count
perform
maygrunwald
giemsa
stain
smear
aliquot
sampl
ml
centrifug
min
g
plasma
harvest
transfer
eppendorf
plain
tube
fcov
serolog
case
assess
baselin
preincub
valu
ifng
specif
presenc
antifcov
antibodi
titr
investig
use
indirect
immunofluoresc
test
perform
multiwel
slide
produc
univers
zurich
accord
osterhau
et
al
use
procedur
routin
perform
laboratori
paltrinieri
et
al
concentr
ifng
measur
method
describ
assess
possibl
non
specif
influenc
peptid
ifng
measur
elisa
techniqu
describ
pool
fresh
felin
plasma
blood
sampl
routin
submit
institut
also
includ
studi
addit
blood
sampl
describ
neg
control
put
cytotox
lymphocyt
ctl
epitop
predict
combin
differ
predict
algorithm
bind
matric
artifici
neural
network
ann
support
vector
machin
svm
follow
program
use
ctlpred
http
wwwimtechresinraghava
ctlpred
bhasin
raghava
rankpep
http
biodfciharvardedurankpep
rech
et
al
ctlpred
abil
predict
ctl
epitop
protein
sequenc
basi
ann
svm
case
consensu
predict
perform
enhanc
specif
result
compar
individu
ann
svm
approach
rankpep
predict
peptid
binder
mhci
molecul
protein
sequenc
use
positionspecif
score
matric
pssm
addit
predict
mhci
ligand
whose
ctermin
end
like
consequ
proteasom
cleavag
amino
acid
sequenc
n
protein
fcov
strain
ncbi
access
detect
faec
healthi
cat
n
extraintestin
organ
obtain
necropsi
cat
lesion
histolog
consist
fip
n
individu
test
use
algorithm
previou
analysi
alreadi
evidenc
presenc
sever
site
posit
select
protein
n
sequenc
might
repres
immunolog
domain
battilani
et
al
criteria
use
select
candid
epitop
higher
bind
score
occur
predict
result
three
time
least
less
two
final
orderdisord
profil
n
protein
use
restrict
panel
peptid
synthes
coronaviru
n
protein
share
modular
organ
presenc
three
intrins
disord
region
locat
central
domain
n
cterminu
sinc
disord
region
often
involv
biomolecular
interact
disord
region
coronaviru
n
protein
alreadi
report
probabl
interact
site
function
implic
tusel
et
al
limit
choic
predict
peptid
region
total
peptid
consist
amino
acid
design
viral
sequenc
center
residu
specif
two
sequenc
virus
detect
necropsi
extra
intestin
organ
cat
lesion
consist
histolog
fip
classifi
virul
strain
fipvlik
three
sequenc
detect
virus
faec
clinic
healthi
cat
classifi
avirul
strain
fecvlik
three
sequenc
detect
virus
tissu
fip
cat
virus
faec
clinic
healthi
cat
classifi
mix
fecvfipv
peptid
synthes
carbonilbas
solidphas
chemistri
thermo
electron
corpor
germani
puriti
peptid
determin
reversedphas
highperform
liquid
chromatographi
mass
spectrometri
detail
peptid
summar
tabl
stock
solut
made
mgml
water
except
peptid
base
amino
acid
composit
result
preliminari
test
small
amount
peptid
less
solubl
water
other
thu
dissolv
dimethylsulfoxid
dmso
water
mixtur
peptid
aliquot
store
perform
cbc
separ
part
blood
fcov
serolog
previous
describ
whole
blood
sampl
subdivid
aliquot
ml
sampl
volum
enough
aliquot
prepar
order
test
effect
peptid
sham
solut
see
sampl
volum
low
aliquot
prepar
order
test
least
one
peptid
sham
solut
aliquot
assay
elisa
plate
well
ad
peptid
sham
solut
neg
control
rnase
free
distil
water
specif
final
concentr
peptid
leukocytesml
well
plate
incub
h
moist
chamber
co
incub
aliquot
resuspend
transfer
eppendorf
tube
aliquot
sampl
dedic
elisa
test
see
centrifug
g
min
obtain
plasma
store
ifng
evalu
perform
order
assess
possibl
non
specif
influenc
peptid
ifng
measur
pool
fresh
plasma
ad
peptid
elisa
test
plasma
ifng
concentr
determin
use
specif
elisa
felin
ifng
duoset
elisa
r
system
europ
ltd
accord
protocol
alreadi
perform
laboratori
giordano
paltrinieri
ifng
measur
perform
duplic
mean
valu
two
read
use
statist
analys
result
rna
extract
use
commerci
avail
kit
qiaamp
rna
blood
mini
kit
qiagen
milan
itali
tabl
sequenc
peptid
design
basi
rna
sequenc
detect
felin
coronavirus
faec
healthi
cat
fecvlik
non
virul
strain
tissu
cat
felin
infecti
periton
fipvlik
virul
strain
fecvfipvlik
mix
strain
revers
gaaggagacaatttggctttgaa
design
previou
studi
gelain
et
al
optim
pcr
protocol
follow
denatur
anneal
cycl
extens
final
extens
step
min
ten
microlitr
reaction
product
visual
agaros
gel
contain
ethidium
bromid
imag
gel
digit
photograph
ultraviolet
transillumin
expect
pcr
product
bp
identifi
use
bp
standard
marker
gene
ruler
bp
dna
ladder
plu
fermenta
uab
vilniu
lit
result
subject
evalu
two
differ
observ
express
neg
band
visibl
weak
band
visibl
lower
intens
compar
bp
ladder
posit
band
intens
compar
bp
ladder
present
result
obtain
well
incub
peptid
compar
obtain
express
unchang
compar
eg
neg
weak
posit
increas
eg
weak
posit
compar
neg
posit
compar
weak
decreas
eg
neg
weak
compar
posit
neg
compar
weak
statist
analys
perform
excel
microsoft
corp
washington
us
analyseit
set
macroinstruct
analyseit
softwar
leed
uk
descript
statist
kolgomorovsmirnov
normal
test
use
examin
distribut
data
regard
concentr
ifng
record
plasma
whole
studi
group
plasma
cat
group
accord
diseas
statu
antifcov
serolog
well
incub
sham
solut
peptid
concentr
ifng
record
plasma
cat
without
diseas
without
antifcov
antibodi
compar
use
mannwitney
utest
result
record
nativ
plasma
plasma
incub
sham
solut
compar
use
wilcoxon
test
latter
test
also
employ
compar
concentr
record
pair
sampl
singl
peptid
sham
solut
test
possibl
presenc
correl
concentr
ifng
plasma
test
well
assess
use
spearmann
correl
test
result
consid
statist
signific
p
due
low
number
observ
semiquantit
method
empoloy
data
rtpcr
test
statist
analyz
result
express
number
increas
decreas
band
intens
compar
eleven
cat
includ
studi
antibodi
titr
lower
equal
repres
cutoff
limit
current
use
author
laboratori
discrimin
infect
infect
cat
cat
show
hematolog
chang
slight
neutrophilia
case
neutrophil
count
rang
cellsl
upper
refer
limit
cellsl
moder
lymphopenia
case
lymphocyt
count
cellsl
respect
lower
refer
limit
cellsl
slight
lymphocytosi
case
lymphocyt
count
cellsl
upper
refer
limit
cellsl
remain
cat
cat
antibodi
titr
hematolog
chang
case
antibodi
titr
evalu
comparison
result
obtain
nativ
pool
fresh
plasma
fresh
pool
plasma
ad
peptid
tabl
show
evid
chang
concentr
ifng
ifng
concentr
record
plasma
incub
peptid
variabl
tabl
cat
nativ
ifng
concentr
test
ifng
concentr
within
refer
interv
healthi
cat
giordano
paltrinieri
plasma
wherea
cat
higher
refer
interv
last
cat
belong
group
diseas
cat
cat
test
clinic
healthi
cat
cat
test
none
show
hematolog
abnorm
signific
differ
ifng
concentr
p
howev
note
diseas
cat
mean
ae
ds
ae
ngml
median
ngml
minmax
rang
ngml
clinic
healthi
cat
ae
ngml
ngml
ngml
spite
evid
differ
mean
median
valu
concentr
ifng
higher
refer
interv
one
fcov
posit
cat
test
differ
ifng
concentr
plasma
record
incub
ae
ngml
incub
sham
solut
ae
ngml
statist
signific
p
result
howev
affect
markedli
increas
ifng
concentr
incub
note
one
sampl
cat
absenc
sampl
concentr
ifng
record
incub
sham
solut
ae
ngml
significantli
lower
p
one
observ
plasma
ae
ngml
signific
correl
amount
ifng
plasma
incub
sham
solut
observ
p
also
differ
concentr
ifng
record
diseas
cat
mean
ae
sd
ae
ngml
median
ngml
refer
interv
ngml
significantli
differ
p
clinic
healthi
cat
ae
ngml
ngml
ngml
similarli
signific
differ
p
found
fcovposit
n
ae
ngml
ngml
ngml
fcovneg
cat
n
ae
ngml
ngml
ngml
comparison
result
obtain
cat
incub
blood
differ
fcov
peptid
report
tabl
mean
median
result
summar
tabl
show
result
obtain
pair
sampl
peptid
determin
compar
mean
valu
ifng
concentr
record
presenc
peptid
decreas
peptid
except
howev
tabl
individu
result
record
studi
cat
concentr
ifng
ngml
record
differ
well
incub
sham
solut
differ
peptid
report
avail
also
concentr
ifng
record
plasma
incub
report
differ
statist
signific
close
statist
signific
analysi
data
distribut
report
fig
howev
reveal
median
valu
lower
peptid
individu
variabl
extrem
high
character
presenc
outlier
eg
peptid
wide
distribut
rang
exampl
interest
note
contrarili
record
peptid
distribut
rang
observ
wider
sampl
treat
sham
solut
explain
fact
cat
ifng
concentr
higher
one
observ
control
well
see
also
tabl
analysi
individu
data
show
valu
higher
also
record
sampl
cat
occasion
cat
mostli
case
incub
peptid
mix
avirul
strain
eg
result
rtpcr
report
tabl
three
cat
show
visibl
band
cell
treat
cat
howev
weak
posit
band
found
aliquot
blood
incub
peptid
specif
compar
peptid
residu
chang
intens
band
except
decreas
intens
one
aliquot
incub
use
peptid
design
around
residu
increas
intens
found
decreas
band
intens
found
one
aliquot
incub
one
regard
peptid
design
around
residu
decreas
intens
found
one
aliquot
incub
increas
intens
band
case
respect
sham
na
na
na
na
na
na
na
hypothes
virul
fcov
strain
aris
genom
mutat
possibl
within
gene
pedersen
pedersen
et
al
chang
et
al
mutat
potenti
involv
pathogen
shift
never
identifi
kennedi
et
al
rottier
et
al
dye
siddel
lin
et
al
experiment
studi
report
low
morbid
rate
cat
inocul
virul
fcov
formerli
classifi
fipv
pedersen
kipar
et
al
dean
et
al
kiss
et
al
find
support
hypothesi
develop
fip
depend
specif
fcovhost
interact
mostli
base
cellmedi
immun
pedersen
pedersen
turn
strength
immun
respons
could
influenc
viral
epitop
sinc
immunemodul
sequenc
found
fcov
genom
zhao
et
al
resistancesuscept
fcov
infect
could
thu
depend
balanc
individu
factor
refer
viru
type
immunomodul
peptid
host
cell
respons
specif
epitop
verifi
hypothesi
assess
rate
ifng
product
felin
blood
cell
incub
peptid
design
sequenc
viral
strain
identifi
faec
clinic
healthi
cat
nonvirul
strain
tissu
cat
fip
virul
strain
sequenc
found
cat
fip
faec
clinic
healthi
cat
thu
design
addit
peptid
classifi
mix
specif
peptid
correspond
residu
protein
n
fcov
select
use
bioinformat
approach
immunom
tool
larg
appli
sever
speci
de
groot
et
al
et
al
cat
thu
studi
epitop
map
algorithm
design
human
mous
use
sinc
sequenc
analysi
felin
mhc
class
reveal
remark
conserv
nucleotid
sequenc
function
organ
human
mous
mhc
loci
yuhki
et
al
obvious
classic
approach
use
overlap
peptid
n
protein
would
provid
exhaust
determin
tcell
epitop
howev
bioinformat
approach
allow
us
save
time
resourc
select
peptid
high
probabl
immunolog
relev
effect
peptid
ifng
product
assess
blood
randomli
collect
routin
activ
random
select
allow
us
reproduc
field
situat
stimuli
necessarili
associ
fcov
infect
influenc
ifng
respons
thu
caseload
includ
cat
chronic
diseas
potenti
character
persist
stimul
immun
system
eg
neoplasia
chronic
inflamm
similarli
fcovneg
fcovposit
cat
sampl
sinc
base
knowledg
hostfcov
interact
like
sampl
respect
noninfect
infect
fcov
addi
et
al
result
nativ
plasma
suggest
concentr
ifng
blood
influenc
presenc
chronic
diseas
rather
serolog
statu
cat
allow
us
assess
whether
respons
immunogen
peptid
fcov
could
influenc
previou
prime
ifng
respons
moreov
moder
hematolog
chang
found
healthi
sick
cat
depend
stress
neutrophilia
lymphopenia
fear
neutrophilia
lymphocytosi
stockham
scott
rather
stimul
immun
system
incub
sham
solut
decreas
concentr
ifng
almost
cat
ifng
concentr
assess
plasma
unlik
depend
analyt
interfer
peptid
sinc
presenc
peptid
pool
fresh
plasma
alter
concentr
ifng
one
cat
cat
higher
concentr
ifng
plasma
spite
lack
evid
hematolog
chang
high
antifcov
titr
unfortun
inform
ifng
concentr
plasma
cat
high
level
ifng
thu
definit
conclud
whether
high
level
due
even
higher
concentr
ifng
plasma
suggest
cat
hyperrespons
plasma
valu
normal
suggest
major
cat
includ
cat
simpl
incub
activ
ifng
product
first
hypothesi
howev
like
base
result
cat
plasma
valu
analyz
rtpcr
result
neg
sampl
consist
report
previou
studi
gelain
et
al
incub
felin
whole
blood
turn
decreas
ifng
concentr
due
degrad
preexist
ifng
coupl
lack
signific
product
ifng
also
hypothesi
support
pcr
result
sampl
thu
protocol
use
studi
maintain
accept
level
ifng
rest
cell
without
stimul
ifng
product
thu
allow
investig
ifng
respons
fcov
peptid
comparison
howev
bias
low
number
observ
individu
variabl
ifng
respons
allow
detect
signific
chang
despit
evid
differ
mean
valu
thu
possibl
draw
definit
conclus
effect
potenti
immunogen
peptid
nevertheless
case
incub
peptid
decreas
concentr
ifng
compar
especi
incub
peptid
design
around
residu
peptid
design
virul
sequenc
around
residu
moreov
case
decreas
ifng
concentr
could
due
degrad
preexist
ifng
possibl
induc
peptid
associ
equival
ifng
product
sinc
rtpcr
suggest
increas
mrna
express
compar
incub
peptid
convers
concentr
ifng
mrna
express
increas
individu
cat
especi
incub
peptid
design
basi
avirul
mix
sequenc
residu
peptid
regard
elisa
test
howev
possibl
presenc
previou
prime
cell
like
sinc
hyperrespons
cat
mostli
found
among
cat
chronic
diseas
potenti
stimul
immun
system
final
base
data
possibl
state
whether
differ
respons
peptid
associ
presenceabs
antifcov
antibodi
specif
diseas
hematolog
chang
cat
show
increas
ifng
product
presenc
given
peptid
respond
way
peptid
suggest
independ
possibl
prime
respons
possibl
peptidespecif
conclus
first
time
silico
predict
vitro
confirm
use
evalu
ifng
product
cat
particular
studi
fcovhost
interact
propos
select
peptid
vitro
assay
employ
studi
thu
use
futur
studi
preliminari
result
respons
fcov
peptid
encourag
investig
possibl
role
protein
n
immunostimul
epitop
specif
although
bias
low
number
observ
high
individu
variabl
result
suggest
sequenc
fcov
protein
n
avirul
mix
strain
stimul
cellmedi
immun
especi
cat
cellmedi
immun
prime
chronic
diseas
futur
larger
studi
requir
confirm
possibl
role
fcov
stimul
product
ifng
key
cytokin
cellmedi
immun
involv
respons
fcov
consequ
respons
viral
persist
gunnmoor
et
al
dean
et
al
foley
et
al
kiss
et
al
berg
et
al
gelain
et
al
giordano
paltrinieri
